Associated Papers
No evidence for the LRRK2 p.L1795F variant in a Southern Italian cohort with Parkinson's disease.
Gagliardi M et al.
Gene, 2026
Association of LRRK2 p.A419V with Parkinson's Disease in East Asians and analysis of age at onset.
Lim KS et al.
Npj Parkinson's Disease, 2026
MC1R loss-of-function is associated with accelerated Parkinson's disease motor decline.
Schumacher JG et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Methodological validation of Miro1 retention as a candidate Parkinson's disease biomarker.
Drwesh L et al.
Npj Parkinson's Disease, 2025
Genome-Wide Association Study of Glucocerebrosidase Activity Modifiers.
Somerville EN et al.
Molecular Neurobiology, 2025
Abundant non-inclusion α-synuclein pathology in Lewy body-negative LRRK2-mutant cases.
Jensen NM et al.
Acta Neuropathologica, 2025
Synaptic deregulation of cholinergic projection neurons causes olfactory dysfunction across five fly Parkinsonism models.
Pech U et al.
Elife, 2025
Intronic SYNE1 Gene Novel Variant Associated with Myocardial Infarction in Young People with a Family History of Premature Atherosclerosis: A Case-Control Study in the Polish Population.
Ambroziak M et al.
International Journal of Molecular Sciences, 2025
Genetic-based diagnostics of Parkinson's disease and other Parkinsonian syndromes.
Somerville EN et al.
Expert Review of Molecular Diagnostics, 2024
Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.
Sosero YL et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2024
Genome-wide association study of glucocerebrosidase activity modifiers.
Somerville EN et al.
Research Square, 2024
p.L1795F LRRK2 variant is a common cause of Parkinson's disease in Central Europe.
Ostrozovicova M et al.
Research Square, 2024
The landscape of rare genetic variation associated with inflammatory bowel disease and Parkinson's disease comorbidity.
Kars ME et al.
Genome Medicine, 2024
Clinical-Genomic Analysis of 1261 Patients with Ehlers-Danlos Syndrome Outlines an Articulo-Autonomic Gene Network (Entome).
Wilson GN et al.
Current Issues in Molecular Biology, 2024
Genetics in Parkinson's disease, state-of-the-art and future perspectives.
Trevisan L et al.
British Medical Bulletin, 2024
Emerging perspectives on precision therapy for Parkinson's disease: multidimensional evidence leading to a new breakthrough in personalized medicine.
Wang Q et al.
Frontiers in Aging Neuroscience, 2024
LRRK2 exonic variants are associated with lysosomal hydrolase activities and lysosphingolipid alterations in Parkinson's disease.
Usenko TS et al.
Gene, 2023
Dopamine pathway and Parkinson's risk variants are associated with levodopa-induced dyskinesia.
Sosero YL et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
LRRK2 and Parkinson's disease: from genetics to targeted therapy.
Sosero YL et al.
Annals of Clinical and Translational Neurology, 2023
Gene Panel Sequencing Analysis Revealed a Strong Contribution of Rare Coding Variants to the Risk of Parkinson's Disease in Sporadic Moroccan Patients.
Smaili I et al.
Journal of Molecular Neuroscience : Mn, 2023
GALC variants affect galactosylceramidase enzymatic activity and risk of Parkinson's disease.
Senkevich K et al.
Brain : a Journal of Neurology, 2023
Genetic Evidence for Endolysosomal Dysfunction in Parkinson's Disease: A Critical Overview.
Yahya V et al.
International Journal of Molecular Sciences, 2023
The genetic basis of multiple system atrophy.
Tseng FS et al.
Journal of Translational Medicine, 2023
Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding.
Kalogeropulou AF et al.
The Biochemical Journal, 2022
Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.
Thakur G et al.
Genes, 2022
Genome Sequencing in the Parkinson Disease Clinic.
Hill EJ et al.
Neurology. Genetics, 2022
Frequency of Parkinson's Disease Genes and Role of PARK2 in Amyotrophic Lateral Sclerosis: An NGS Study.
Vacchiano V et al.
Genes, 2022
LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease.
Kedariti M et al.
Npj Parkinson's Disease, 2022
Lysosomal dysfunction in neurodegeneration: emerging concepts and methods.
Udayar V et al.
Trends in Neurosciences, 2022
Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.
Lake J et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2022
Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease.
Smith LJ et al.
Frontiers in Neurology, 2022
Parkinson's Disease Genetics and Pathophysiology.
Vázquez-Vélez GE et al.
Annual Review of Neuroscience, 2021
LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease.
Sosero YL et al.
Neurobiology of Aging, 2021
Identification of LRRK2 missense variants in the accelerating medicines partnership Parkinson's disease cohort.
Bryant N et al.
Human Molecular Genetics, 2021
Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells.
Goveas L et al.
Cells, 2021
Is LRRK2 the missing link between inflammatory bowel disease and Parkinson's disease?
Herrick MK et al.
Npj Parkinson's Disease, 2021
Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease.
Heckman MG et al.
Parkinsonism & Related Disorders, 2021
Clinical and Genetic Analysis of Costa Rican Patients With Parkinson's Disease.
Torrealba-Acosta G et al.
Frontiers in Neurology, 2021
Precision Health Resource of Control iPSC Lines for Versatile Multilineage Differentiation.
Hildebrandt MR et al.
Stem Cell Reports, 2019
The Missing Heritability of Sporadic Frontotemporal Dementia: New Insights from Rare Variants in Neurodegenerative Candidate Genes.
Ciani M et al.
International Journal of Molecular Sciences, 2019